Scarica l'app Stockscreener
1.285
0.39%
0.005
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Galectin Therapeutics Inc Borsa (GALT) Ultime notizie
Galectin Therapeutics (GALT) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Galectin Therapeutics (GALT) Advances in Belapectin Analysis | G - GuruFocus
Galectin Therapeutics (GALT) Advances in Belapectin Analysis | GALT Stock News - GuruFocus
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update - The Manila Times
Galectin Therapeutics Reports Q1 2025 Financial Results and Business Update - TradingView
GALECTIN THERAPEUTICS INC SEC 10-Q Report - TradingView
Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Barclays PLC Purchases 26,047 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics (GALT) Projected to Post Quarterly Earnings on Wednesday - Defense World
Belapectin shows promise in MASH cirrhosis trial By Investing.com - Investing.com Canada
Galectin Therapeutics Presents NAVIGATE Study Data Of Belapectin At EASL 2025 Congress - Nasdaq
Galectin Therapeutics (GALT) Reveals Promising NAVIGATE Study Re - GuruFocus
Belapectin shows promise in MASH cirrhosis trial - Investing.com Australia
Galectin Therapeutics Updates Corporate Presentation on Belapectin - TipRanks
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress - The Manila Times
Galectin Therapeutics Inc. Reports Positive NAVIGATE Trial Results for Belapectin in MASH Cirrhosis Treatment - Nasdaq
Galectin Therapeutics Inc. (NASDAQ:GALT) Stock Position Boosted by JPMorgan Chase & Co. - Defense World
Renaissance Technologies LLC Decreases Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - The AM Reporter
9 Short Squeeze Stocks That Could Take Off - US News Money
Geode Capital Management LLC Has $1.12 Million Stake in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
LPL Financial LLC Has $179,000 Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
RBC Capital Keeps Their Buy Rating on Brookfield Infrastructure (BIP) - The Globe and Mail
Will Alphabet Stock Keep Rising After Crushing Q1 Earnings Expectations? - The Globe and Mail
CEO.CA's Inside the Boardroom: Yukon Metals CEO Breaks Down Upcoming Drilling Plans for Star River Gold-Silver and AZ Copper Targets - The Globe and Mail
MASH Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Statistics, Revenue, Patient Pool, MOA, ROA and Companies by DelveInsight - The Globe and Mail
Commonwealth Equity Services LLC Reduces Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - MarketBeat
Game-Changing MASH Cirrhosis Treatment Results: New Clinical Data Shows Promise in Portal Hypertension - Stock Titan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Commonwealth Equity Services LLC - Defense World
HC Wainwright Analysts Boost Earnings Estimates for GALT - MarketBeat
FY2029 Earnings Forecast for GALT Issued By HC Wainwright - MarketBeat
Psoriasis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Galectin Therapeutics (NASDAQ:GALT) Earns "Neutral" Rating from HC Wainwright - MarketBeat
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
HC Wainwright Analysts Raise Earnings Estimates for GALT - Defense World
Q2 EPS Forecast for Galectin Therapeutics Boosted by Analyst - The AM Reporter
HighTower Advisors LLC Buys Shares of 22,486 Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Equities Analysts Set Expectations for GALT FY2029 Earnings - Defense World
Galectin Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Galectin Therapeutics (NASDAQ:GALT) Issues Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
HC Wainwright Reiterates “Neutral” Rating for Galectin Therapeutics (NASDAQ:GALT) - Defense World
SPY ETF News, 4/3/2025 - The Globe and Mail
Galectin Therapeutics Reports Promising 2024 Results - TipRanks
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update - The Manila Times
Breakthrough: Galectin's MASH Drug Shows 68% Disease Reduction in US Patients - Stock Titan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Bank of New York Mellon Corp - Defense World
PNC Financial Services Group Inc. Takes $26,000 Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics (GALT) to Release Quarterly Earnings on Friday - Defense World
Best Statistical Liver Cirrhosis Market Growth Set to Surge - openPR.com
Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap up US$10m last week, benefiting both retail investors who own 54% as well as insiders - Simply Wall St
Public market insider buying at Montero Mining & Explorat (MON) - The Globe and Mail
While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership - Yahoo Finance
Sanctuary Advisors LLC Sells 20,700 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
0.88%
0.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):